Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: Evaluation of the long-term outcome

Pier Luigi Zinzani, Letizia Gandolfi, Vittorio Stefoni, Stefano Fanti, Mariapaola Fina, Cinzia Pellegrini, Gian Carlo Montini, Enrico Derenzini, Alessandro Broccoli, Lisa Argnani, Stefano Pileri, Michele Baccarani

Research output: Contribution to journalArticle

Abstract

Background: Based on historical data on the role of radioimmunotherapy (RIT) in pretreated non-Hodgkin lymphoma, we reviewed our hospital's clinical database. Patients and Methods: Between 2005 and 2008, 57 patients previously treated with at least 1 rituximab-containing chemotherapy were treated with Yttrium-90-labeled ibritumomab tiuxetan (90Y-IT). The median number of pretreatments was 3 (range, 1-9 pretreatments). A total of 46 patients had stage III/IV disease (31 with bone marrow involvement); 6 had bulky disease. According to histology, 53 were follicular lymphoma (FL), 2 were marginal zone lymphoma, and 2 were small lymphocytic lymphoma. Results: Overall response rate was 93% (53 of 57); complete response (CR) rate was 70% (40 of 57). Twenty-six of 40 patients (65%) who obtained a CR are in continuous CR (CCR) with a median follow-up of 20 months (range, 10-42 months); 4 of them still maintain their CCR after 36 months. All patients achieving a CCR had FL, and 21 of them with stage III/IV disease; 12 of 26 had been heavily pretreated (≥ 3 previous treatments), and 2 had had autologous stem cell transplantation. Toxicity was primarily hematologic and mostly transient; no grade 4 extrahematologic toxicity was observed. Conclusion: This study confirms the safety and high efficacy of 90Y-IT RIT in heavily pretreated FL patients, with the possibility of having a subset of long-term responders.

Original languageEnglish
Pages (from-to)258-261
Number of pages4
JournalClinical Lymphoma, Myeloma and Leukemia
Volume10
Issue number4
DOIs
Publication statusPublished - Aug 2010

Fingerprint

B-Cell Lymphoma
Proxy
Follicular Lymphoma
Radioimmunotherapy
Stem Cell Transplantation
B-Cell Chronic Lymphocytic Leukemia
Non-Hodgkin's Lymphoma
ibritumomab tiuxetan
Lymphoma
Histology
Bone Marrow
Databases
Safety
Drug Therapy

Keywords

  • Follicular lymphoma
  • Non-Hodgkin lymphoma
  • Pretreated indolent lymphoma
  • Radioimmunotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Hematology

Cite this

Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma : Evaluation of the long-term outcome. / Zinzani, Pier Luigi; Gandolfi, Letizia; Stefoni, Vittorio; Fanti, Stefano; Fina, Mariapaola; Pellegrini, Cinzia; Montini, Gian Carlo; Derenzini, Enrico; Broccoli, Alessandro; Argnani, Lisa; Pileri, Stefano; Baccarani, Michele.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 10, No. 4, 08.2010, p. 258-261.

Research output: Contribution to journalArticle

Zinzani, PL, Gandolfi, L, Stefoni, V, Fanti, S, Fina, M, Pellegrini, C, Montini, GC, Derenzini, E, Broccoli, A, Argnani, L, Pileri, S & Baccarani, M 2010, 'Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: Evaluation of the long-term outcome', Clinical Lymphoma, Myeloma and Leukemia, vol. 10, no. 4, pp. 258-261. https://doi.org/10.3816/CLML.2010.n.054
Zinzani, Pier Luigi ; Gandolfi, Letizia ; Stefoni, Vittorio ; Fanti, Stefano ; Fina, Mariapaola ; Pellegrini, Cinzia ; Montini, Gian Carlo ; Derenzini, Enrico ; Broccoli, Alessandro ; Argnani, Lisa ; Pileri, Stefano ; Baccarani, Michele. / Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma : Evaluation of the long-term outcome. In: Clinical Lymphoma, Myeloma and Leukemia. 2010 ; Vol. 10, No. 4. pp. 258-261.
@article{c2c4d8810ce24976ad77a070122a37ef,
title = "Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: Evaluation of the long-term outcome",
abstract = "Background: Based on historical data on the role of radioimmunotherapy (RIT) in pretreated non-Hodgkin lymphoma, we reviewed our hospital's clinical database. Patients and Methods: Between 2005 and 2008, 57 patients previously treated with at least 1 rituximab-containing chemotherapy were treated with Yttrium-90-labeled ibritumomab tiuxetan (90Y-IT). The median number of pretreatments was 3 (range, 1-9 pretreatments). A total of 46 patients had stage III/IV disease (31 with bone marrow involvement); 6 had bulky disease. According to histology, 53 were follicular lymphoma (FL), 2 were marginal zone lymphoma, and 2 were small lymphocytic lymphoma. Results: Overall response rate was 93{\%} (53 of 57); complete response (CR) rate was 70{\%} (40 of 57). Twenty-six of 40 patients (65{\%}) who obtained a CR are in continuous CR (CCR) with a median follow-up of 20 months (range, 10-42 months); 4 of them still maintain their CCR after 36 months. All patients achieving a CCR had FL, and 21 of them with stage III/IV disease; 12 of 26 had been heavily pretreated (≥ 3 previous treatments), and 2 had had autologous stem cell transplantation. Toxicity was primarily hematologic and mostly transient; no grade 4 extrahematologic toxicity was observed. Conclusion: This study confirms the safety and high efficacy of 90Y-IT RIT in heavily pretreated FL patients, with the possibility of having a subset of long-term responders.",
keywords = "Follicular lymphoma, Non-Hodgkin lymphoma, Pretreated indolent lymphoma, Radioimmunotherapy",
author = "Zinzani, {Pier Luigi} and Letizia Gandolfi and Vittorio Stefoni and Stefano Fanti and Mariapaola Fina and Cinzia Pellegrini and Montini, {Gian Carlo} and Enrico Derenzini and Alessandro Broccoli and Lisa Argnani and Stefano Pileri and Michele Baccarani",
year = "2010",
month = "8",
doi = "10.3816/CLML.2010.n.054",
language = "English",
volume = "10",
pages = "258--261",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",
number = "4",

}

TY - JOUR

T1 - Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma

T2 - Evaluation of the long-term outcome

AU - Zinzani, Pier Luigi

AU - Gandolfi, Letizia

AU - Stefoni, Vittorio

AU - Fanti, Stefano

AU - Fina, Mariapaola

AU - Pellegrini, Cinzia

AU - Montini, Gian Carlo

AU - Derenzini, Enrico

AU - Broccoli, Alessandro

AU - Argnani, Lisa

AU - Pileri, Stefano

AU - Baccarani, Michele

PY - 2010/8

Y1 - 2010/8

N2 - Background: Based on historical data on the role of radioimmunotherapy (RIT) in pretreated non-Hodgkin lymphoma, we reviewed our hospital's clinical database. Patients and Methods: Between 2005 and 2008, 57 patients previously treated with at least 1 rituximab-containing chemotherapy were treated with Yttrium-90-labeled ibritumomab tiuxetan (90Y-IT). The median number of pretreatments was 3 (range, 1-9 pretreatments). A total of 46 patients had stage III/IV disease (31 with bone marrow involvement); 6 had bulky disease. According to histology, 53 were follicular lymphoma (FL), 2 were marginal zone lymphoma, and 2 were small lymphocytic lymphoma. Results: Overall response rate was 93% (53 of 57); complete response (CR) rate was 70% (40 of 57). Twenty-six of 40 patients (65%) who obtained a CR are in continuous CR (CCR) with a median follow-up of 20 months (range, 10-42 months); 4 of them still maintain their CCR after 36 months. All patients achieving a CCR had FL, and 21 of them with stage III/IV disease; 12 of 26 had been heavily pretreated (≥ 3 previous treatments), and 2 had had autologous stem cell transplantation. Toxicity was primarily hematologic and mostly transient; no grade 4 extrahematologic toxicity was observed. Conclusion: This study confirms the safety and high efficacy of 90Y-IT RIT in heavily pretreated FL patients, with the possibility of having a subset of long-term responders.

AB - Background: Based on historical data on the role of radioimmunotherapy (RIT) in pretreated non-Hodgkin lymphoma, we reviewed our hospital's clinical database. Patients and Methods: Between 2005 and 2008, 57 patients previously treated with at least 1 rituximab-containing chemotherapy were treated with Yttrium-90-labeled ibritumomab tiuxetan (90Y-IT). The median number of pretreatments was 3 (range, 1-9 pretreatments). A total of 46 patients had stage III/IV disease (31 with bone marrow involvement); 6 had bulky disease. According to histology, 53 were follicular lymphoma (FL), 2 were marginal zone lymphoma, and 2 were small lymphocytic lymphoma. Results: Overall response rate was 93% (53 of 57); complete response (CR) rate was 70% (40 of 57). Twenty-six of 40 patients (65%) who obtained a CR are in continuous CR (CCR) with a median follow-up of 20 months (range, 10-42 months); 4 of them still maintain their CCR after 36 months. All patients achieving a CCR had FL, and 21 of them with stage III/IV disease; 12 of 26 had been heavily pretreated (≥ 3 previous treatments), and 2 had had autologous stem cell transplantation. Toxicity was primarily hematologic and mostly transient; no grade 4 extrahematologic toxicity was observed. Conclusion: This study confirms the safety and high efficacy of 90Y-IT RIT in heavily pretreated FL patients, with the possibility of having a subset of long-term responders.

KW - Follicular lymphoma

KW - Non-Hodgkin lymphoma

KW - Pretreated indolent lymphoma

KW - Radioimmunotherapy

UR - http://www.scopus.com/inward/record.url?scp=77957092383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957092383&partnerID=8YFLogxK

U2 - 10.3816/CLML.2010.n.054

DO - 10.3816/CLML.2010.n.054

M3 - Article

C2 - 20709661

AN - SCOPUS:77957092383

VL - 10

SP - 258

EP - 261

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

IS - 4

ER -